Institute for the Study of Urological Diseases, Greece
Dimitrios Hatzichristou
We designed a double blind randomized sham-controlled trial in order to investigate and compare the treatment efficacy of LiST plus PRP intracorporeal injection vs LiST plus placebo (normal saline intracorporeal injection) in men with moderate and mild to moderate vasculogenic ED, as measured by IIEF-EF.
Erectile Dysfunction
LiST + PRP intracorporeal injection
LiST + Placebo(normal saline intracorporeal injection)
Phase 2
Phase 3
Study Type : | Interventional |
Estimated Enrollment : | 60 participants |
Masking: | Quadruple |
Primary Purpose: | Treatment |
Official Title: | Is Combined Low Intensity Shockwave Therapy (LiST) Plus Platelet-rich Plasma (PRP) Injection Therapy Better Than LiST Monotherapy for the Improvement of Erectile Function? a Double-blind, Randomized, Placebo-controlled Clinical Trial |
Actual Study Start Date : | September 2022 |
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | March 2024 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Group A |
Combination Product: LiST + PRP intracorporeal injection |
Placebo Comparator: Group B |
Combination Product: LiST + Placebo(normal saline intracorporeal injection) |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.